Noticeably, there is an active phase II clinical trial (NCT03213665-MATCH) aiming to determine the performance of tazemetostat in pediatric NHL patients harboring SMARCB1 or SMARCA4 gene mutations. Here, SMARCA4 is linked to non-Hodgkin lymphoma.